» Articles » PMID: 34439972

Brain Organoids: Filling the Need for a Human Model of Neurological Disorder

Overview
Journal Biology (Basel)
Publisher MDPI
Specialty Biology
Date 2021 Aug 27
PMID 34439972
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Neurological disorders are among the leading causes of death worldwide, accounting for almost all onsets of dementia in the elderly, and are known to negatively affect motor ability, mental and cognitive performance, as well as overall wellbeing and happiness. Currently, most neurological disorders go untreated due to a lack of viable treatment options. The reason for this lack of options is s poor understanding of the disorders, primarily due to research models that do not translate well into the human in vivo system. Current models for researching neurological disorders, neurodevelopment, and drug interactions in the central nervous system include in vitro monolayer cell cultures, and in vivo animal models. These models have shortcomings when it comes to translating research about disorder pathology, development, and treatment to humans. Brain organoids are three-dimensional (3D) cultures of stem cell-derived neural cells that mimic the development of the in vivo human brain with high degrees of accuracy. Researchers have started developing these miniature brains to model neurodevelopment, and neuropathology. Brain organoids have been used to model a wide range of neurological disorders, including the complex and poorly understood neurodevelopmental and neurodegenerative disorders. In this review, we discuss the brain organoid technology, placing special focus on the different brain organoid models that have been developed, discussing their strengths, weaknesses, and uses in neurological disease modeling.

Citing Articles

iPSC-derived human cortical organoids display profound alterations of cellular homeostasis following SARS-CoV-2 infection and Spike protein exposure.

Cappelletti G, Brambilla L, Strizzi S, Limanaqi F, Melzi V, Rizzuti M FASEB J. 2025; 39(4):e70396.

PMID: 39950320 PMC: 11826378. DOI: 10.1096/fj.202401604RRR.


Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.

Maity S, Bhuyan T, Jewell C, Kawakita S, Sharma S, Nguyen H Small. 2024; 21(1):e2405511.

PMID: 39535474 PMC: 11719323. DOI: 10.1002/smll.202405511.


The SVZ stem cell niche-components, functions, and modelling.

Esiyok N, Heide M Front Cell Dev Biol. 2024; 11:1332901.

PMID: 38188021 PMC: 10766702. DOI: 10.3389/fcell.2023.1332901.


From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.

Tanaka M, Szabo A, Kortesi T, Szok D, Tajti J, Vecsei L Cells. 2023; 12(22).

PMID: 37998384 PMC: 10670698. DOI: 10.3390/cells12222649.


Brain organoids for hypoxic-ischemic studies: from bench to bedside.

Gaston-Breton R, Maiza Letrou A, Hamoudi R, Stonestreet B, Mabondzo A Cell Mol Life Sci. 2023; 80(11):318.

PMID: 37804439 PMC: 10560197. DOI: 10.1007/s00018-023-04951-0.


References
1.
Kim H, Park H, Choi H, Chang Y, Park H, Shin J . Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids. Stem Cell Reports. 2019; 12(3):518-531. PMC: 6410341. DOI: 10.1016/j.stemcr.2019.01.020. View

2.
Chambers S, Fasano C, Papapetrou E, Tomishima M, Sadelain M, Studer L . Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80. PMC: 2756723. DOI: 10.1038/nbt.1529. View

3.
Bithell A, Williams B . Neural stem cells and cell replacement therapy: making the right cells. Clin Sci (Lond). 2004; 108(1):13-22. DOI: 10.1042/CS20040276. View

4.
Fan Y, Winanto , Ng S . Replacing what's lost: a new era of stem cell therapy for Parkinson's disease. Transl Neurodegener. 2020; 9:2. PMC: 6945567. DOI: 10.1186/s40035-019-0180-x. View

5.
Xu R, Brawner A, Li S, Liu J, Kim H, Xue H . OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome. Cell Stem Cell. 2019; 24(6):908-926.e8. PMC: 6944064. DOI: 10.1016/j.stem.2019.04.014. View